An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Senseonics Holdings, Inc. (SENS) plans to release its Q3 2023 financial results on November 9, 2023. The company is focused on the development and manufacturing of long-term, implantable continuous glucose monitoring systems for people with diabetes. A conference call will be held to review the performance, which will be webcasted and archived on the company's website.
Positive
None.
Negative
None.
GERMANTOWN, Md.--(BUSINESS WIRE)--
Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its third quarter 2023 financial results after market close on Thursday, November 9, 2023.
Management will hold a conference call to review the Company’s third quarter 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. To listen to the conference call, please dial 1-888-317-6003 (US/Canada) or 1-412-317-6061 (International), passcode 1409312, approximately ten to five minutes prior to start time.
About Senseonics
Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems, Eversense®, Eversense® XL and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
Senseonics Holdings plans to release its Q3 2023 financial results on November 9, 2023.
Senseonics Holdings is focused on the development and manufacturing of long-term, implantable continuous glucose monitoring systems for people with diabetes.
Yes, there will be a conference call to review Senseonics Holdings' Q3 2023 performance.
The webcast of the conference call will be available on Senseonics Holdings' website at www.senseonics.com under 'Investor Relations' and 'Events & Publications'.
senseonics, inc. is a medical device startup company in germantown, maryland, usa (near washington, dc) developing transformative glucose monitoring products that are intended to enable people with diabetes to confidently live their lives with ease. utilizing breakthrough fluorescence sensing technology, the senseonics continuous glucose monitoring ("cgm") system is being designed to be the first fully implantable cgm that is highly accurate and stable throughout its long sensor life. the system consists of a very small sensor implanted under the skin, an external transmitter, and a mobile medical application, which allows for discreet, easy access to real-time glucose measurements without the need for a dedicated receiver.
